Dermatitis  >>  omiganan (CLS001)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
omiganan (CLS001) / Maruho
NCT02456480 / 2014-003689-26: Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Completed
2
37
Europe
CLS001, Vehicle
Maruho Co., Ltd.
Atopic Dermatitis
11/15
11/15
NCT03091426 / 2016-003849-28: Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Completed
2
80
Europe
Omiganan, Placebo
Maruho Co., Ltd.
Atopic Dermatitis
12/17
12/17
2017-003106-41: Omiganan BID in patients with facial seborrheic dermatitis

Ongoing
2
36
Europe
Omiganan Topical Gel, Nizoral 20 mg/g, crème, CLS001, Nizoral 20 mg/g, crème, Gel, Cream, Nizoral 20 mg/g, crème
Cutanea Life Sciences, Cutanea Life Sciences
Mild to moderate facial seborrheic dermatitis., facial seborrheic dermatitis, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT03688971: Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

Unknown status
2
36
Europe
Omiganan, Ketoconazole, Placebo
Maruho Co., Ltd.
Seborrheic Dermatitis
12/19
12/19

Download Options